Ranjith Kumavath

Central University of KeralaIndia

Dr. Ranjith Kumavath, MSc, PhD, FASB, was born in 1979 to a lovely Rajput Indian couple and grew up in south India. He received his PhD degree from the University of Hyderabad. Before joining CUK in 2011, he worked as a postdoctoral research fellow at the University of Hyderabad, Singapore and the USA. He has been awarded as Young Scientist by DST, Govt. of India; BioAsia Young Scientist by govt. of Andhra Pradesh; Fellow of the Society of Applied Biotechnology by SAB; Fellow of Young Investigator by India Biosciences and Mahatma Gandhi Gold Medal Award 2014; and APJ Abdul Kalam Award by GEPRA, India. Currently, he is operating four major research projects funded by UGC-BSR, SERB-DST and SERB, Govt. of India. He has published 2 books, 6 chapters and 23 research publications in leading international journals, and he has made 18 national and 16 international presentations. He has contributed in discovery of four novel enzymes to IUBMB. He has collaborations with UoH, IIOAB, Cancer Science Institute of Singapore and San Diego State University, USA. His main research interest areas are cancer genomics, microbial genetics and metagenomics, human infective diseases and computational drug designing. His research group is being dedicated towards developing anti-cancer agents from microbial recourses for target-based drug discovery.

2books edited

3chapters authored

Latest work with IntechOpen by Ranjith Kumavath

New drugs are frequently entering into the market along with the existing drugs. The antibacterial agents can be discussed in five major classes, i.e. classification based on the type of action, source, spectrum of activity, chemical structure and function. Resistance of bacteria to antibiotics is an urgent problem of the humanity, which leads us to the lack of therapy for serious bacterial infections. Development of new antibiotics has almost ceased in the last decades - even when a new antibiotic is launched, very soon the resistance of bacteria appears. Industrial textiles exposed as awnings, screens, tents; upholstery used in large public areas such as hospitals, hotels and stations; fabrics for transports; protective clothing and personal protective equipment; bed sheets and blankets; textiles left wet between processing steps; intimate apparel, underwear, socks and sportswear, disinfection of air and water for white rooms, hospitals and operating theatres, food and pharma industries, water depuration, drinkable water supplying and air conditioning systems. Many clinicians recommend alternative approaches to using antimicrobial substances. Moreover, the majority of bioagents demonstrate on antibiotics for treatment of a wide range of diseases in human sectors. However, the misuse and mishandling of drugs lead to microbial, particularly bacterial, resistance as well as result in the difficulty of treating microbial diseases. Hence, the proposed book will give more precise information on novel antibacterial compound(s).

Go to the book